Supplementary Information - Table 1: Viruses Used and Their Associated Characteristics

4 viruses were selected to represent different biophysical and biochemical properties.

| Virus | Strain | Nucleic Acid | Size of Genome (Kb) (accession number) | Enveloped |
|--------------------------------|---------|---|--|-----------|
| Epstein-Barr Virus | B95-8 | Double-stranded DNA | 172.3 (V01555.2) | Yes |
| Feline Leukemia Virus | Thielen | Single-stranded RNA (+ve; retrovirus) | 8.2 (NC_001940.1) | Yes |
| Respiratory Syncytial Virus | A2 | Single-stranded RNA (-ve) | 15.2 (KF826849.1) | Yes |
| Reovirus 3 | Dearing | Double-stranded RNA | 23 - in 10 segments (GCF_000924305.1) | No |

Supplementary Information - Table 2: Extraction Approaches Evaluated

11 extraction approaches were evaluated for unbiased extraction of viral nucleic acid extraction.

A rationale is provided for their inclusion in this study.

| Supplier | Kit Name | Chemistry | Rationale for Inclusion in Study |
|-----------------------|-----------------------------|---------------|----------------------------------|
| QIAGEN | QIAamp® | Silica | Typically used sample |
| (Toronto, Canada) | MinElute® Virus | | preparation method |
| | Spin Kit | | |
| QIAGEN | QIAamp® | Silica | Up to 5 mL starting volume |
| (Toronto, Canada) | Circulating Nucleic | | |
| | Acid | | |
| QIAGEN | RNeasy® Mini Kit | Silica | RNA extraction |
| (Toronto, Canada) | | | |
| ClonTech Laboratories | NucleoBond® | Silica | DNA and RNA separately |
| (Mountain View, USA) | RNA/DNA | | eluted |
| ClonTech Laboratories | NucleoSpin® RNA | Silica | 1 mL starting volume |
| (Mountain View, USA) | Virus F | | |
| Life Technologies | PureLink [™] Viral | Silica | Lysis buffer is optimized for |
| (Carlsbad, USA) | RNA/DNA Mini Kit | | the lysis of viruses |
| Life Technologies | Dynabeads® | Silica like | Not Silica; No membrane |
| (Carlsbad, USA) | SILANE Viral NA | beads | clogging by cell debris |
| | Kit | | |
| Wako Chemicals | DNA Extractor® | Precipitation | DNA extraction |
| (Richmond, USA) | | | |
| Perkin Elmer | Chemagic [™] Viral | Silica beads | No membrane clogging by |
| (Waltham, USA) | DNA/RNA kit | | cell debris |
| Life Technologies | Phenol-Chloroform | Organic | Potentially cleaner of salts |
| (Carlsbad, USA) | | solvent | and cell components; Large |
| | | | starting volume (Isolate |
| | | | DNA/RNA) |
| Life Technologies | Acid Phenol- | Organic | Potentially cleaner of salts |
| (Carlsbad, USA) | Chloroform (pH 5) | solvent | and cell components; Large |
| | | | starting volume (Isolate |
| | | | RNA) |

Supplementary Information – Table 3: Sequencing results for the MinElute + WGA and Optimized Procedure replicates

Reads Per Kilobase Million (RPKM) is an indication of the bias observed between the different virus types (reported below in Parentheses). In the MinElute+WGA procedure, there is a large difference between the recovery of EBV and RSV / Reo3 even after normalizing for genome size. In our optimized procedure, the recovery of all viral types is more balanced with enhancement for Reo3 and RSV.

| Virus | MinElute + WGA | | | |
|------------------|-----------------------------|-----------------------------|-----------------------------|--|
| | Replicate #1 | Replicate #2 | Replicate #3 | |
| Total Number of | 217113184 | 217740212 | 303618486 | |
| sequencing Reads | | | | |
| EBV (172Kb) | 1266738 | 566528 | 758085 | |
| | (33.6) | (15.1) | (14.5) | |
| RSV (8.2Kb) | 510 | 3308 | 5316 | |
| | (5.07 x 10 ⁻⁴) | (7.38×10^{-3}) | $(1.23 \text{ x } 10^{-2})$ | |
| FeLV (15.2Kb) | 994 | 5572 | 11322 | |
| | (66.0) | (25.4) | (30.9) | |
| Reo3 (23Kb) | 2 | 90 | 283 | |
| | $(1.02 \text{ x } 10^{-6})$ | $(1.19 \text{ x } 10^{-4})$ | $(3.09 \text{ x } 10^{-4})$ | |

| Virus | Optimized Procedure | | | |
|------------------|---------------------|--------------|--------------|--------------|
| | Replicate #1 | Replicate #2 | Replicate #3 | Replicate #4 |
| Total Number of | 239327708 | 306409538 | 173469346 | 283646346 |
| sequencing Reads | | | | |
| EBV (172Kb) | 1049436 | 1043475 | 312890 | 1154295 |
| | (25.4) | (19.8) | (10.5) | (23.6) |
| RSV (8.2Kb) | 22579 | 30172 | 8575 | 17780 |
| | (11.5) | (12.0) | (6.0) | (7.6) |
| | | | | |
| FeLV (15.2Kb) | 71024 | 137028 | 75032 | 75388 |
| | (19.5) | (29.4) | (28.5) | (17.5) |
| Reo3 (23Kb) | 752834 | 580200 | 783999 | 1576400 |
| | (136.7) | (82.3) | (196.5) | (241.6) |

Supplementary Information – Table 4: Extraction Approaches Tested and Modifications to the Manufacturer's Protocol

| PureLink [™] Viral | Starting volume: 200 µL. Final spin to completely dry the column and the elution of the nucleic acid was carried out |
|------------------------------|---|
| RNA/DNA | at 16 100 \times g for 1 min. |
| QIAamp® | Starting volume: 200 μ L. Intermediate spins were carried out at 6800 \times g. The columns were dried for 3 min at room |
| MinElute® Virus Spin | temperature (rt). The final elution volume was incubated on the column at rt for 5 min and elution was at $16\ 100 \times g$ |
| Dynabeads® SILANE | Starting volume: 200 µL. Magnetic beads were dried for 15 min on the magnetic stand, then removed from the stand |
| Viral NA | and dried for a further 5 min. |
| QIAamp® Circulating | Starting volume: 3 mL. The protocol for 3 mL of sample was followed. Columns were dried at rt for 10 min and the |
| Nucleic Acid | final elution was at $16\ 100 \times g$. |
| Chemagic TM Viral | Starting volume: 200 µL. Elution was carried out with intermediate agitation. |
| DNA/RNA | |
| RNeasy [®] Mini | Starting volume: 100 µL. Sample supernatant was combined with 15 µL of Proteinase K and incubated at rt for 10 |
| | min to digest the viral capsid. An on-column DNase digest was carried out. The second RWI wash was incubated on |
| | the column for 5 min at rt and the 2 final spins were conducted at 16 100 \times g. The final elution volume was 50 μ L. |
| Wako DNA | Scheme 1 of the manufacturer's protocol was followed with the following modifications: Sample was combined with |
| Extractor® | 20 µL Proteinase K and 0.84 µL of RNase A and incubated at 60°C for 20 min. DNA pellet was first washed with 1 |
| | mL of Wash Solution A, followed by a second wash with 1 mL of Wash Solution B with 0.5 µL of the glycogen |
| | solution. The final pellet was air-dried for 5 min and dissolved in water. |
| NucleoSpin® RNA | Starting volume: 1 mL. 133 µL of Proteinase K was combined with 4 mL of RAV1. To remove residual Buffer |
| Virus F | RAV3, the column was placed in a clean collection tube and spun at $3000 \times g$ for an additional 10 min. Final elution |
| | volume was with 50 µL of water pre-heated to 70°C. |
| NucleoBond® | Starting volume: 100 µL. Sample was combined with 25 µL of Proteinase K and 500 µL of Buffer W1 and incubated |
| RNA/DNA 80 | at 60°C for 15 min. Flow through was collected after each wash with Buffer R1, Buffer R1:R2, Buffer R2. |
| | Precipitated nucleic acid was pelleted by centrifugation at $3148 \times g$. Final pellet was resuspended in water. |
| (Acid) | An in-house protocol was employed. 100 µL of sample supernatant was combined with 25 µL of Proteinase K and |
| Phenol:Chloroform | 200 µL of the lysis buffer (from the PureLink [™] Viral RNA/DNA kit) and incubated at 56°C for 15 min. 300 µL of |
| Extraction | (Acid) Phenol:Chloroform was added and vortexed for 1 min. Sample was centrifuged for 5 min at rt at $16100 \times g$. |
| | Aqueous phase was combined with $2-2.5 \times$ volume of ice-cold ethanol. Mixture was incubated at -20° C overnight and |
| | centrifuged for 30 min at 20 000 \times g at 4°C. Pellet was washed with cold 80% ethanol and centrifuged for 15 min at |
| | $20\ 000 \times g$ at 4°C. Supernatant was removed and pellet was dried for 15 min at rt. Final pellet was dissolved in water |
| | and incubated at 50°C for 10 min. |

Supplementary Information – Table 5: Virus-Specific Primers

Virus-specific primers used for qPCR assessment of virus recovery.

| Virus | Gene | Accession # | Primer Sequence $5' \rightarrow 3'$ |
|-------|--------|-------------|-------------------------------------|
| EBV | EBNA-1 | NC_007605.1 | AGCGTTTCTTGAGCTTCCCT |
| | | | TGATGCGACGATCACAGGTC |
| EBV | EBNA-1 | NC_007605.1 | CTGGGATGAGCGTTTGG |
| | | | CTGGCGGTCTATGATGC |
| EBV | EBNA-1 | NC_007605.1 | CAGCCCAGAGAGTAGTCTCAG |
| | | | GTGAATCTGCTCCCAGGTCT |
| FeLV | LTR | NC_001940.1 | CCCGTGTACGAATAAACCTC |
| | | | CCCTGAACTAGGTCTTCCT |
| FeLV | LTR | NC_001940.1 | TACCAGCAGTCTCCAGGCT |
| | | | ACAGAAGCGAGAGGCGTG |
| RSV | Ν | KJ627707.1 | CAGGGCAAGTGATGTTACG |
| | | | CATAAACTTCCACAACTTGTTCC |
| RSV | Ν | KJ627707.1 | TGCAGGATTGTTTATGAATGC |
| | | | CCATTTCTGCTTGCACACTA |
| Reo3 | M3 | AF174384.1 | CCTATCTACTAGAGTGTCTACCC |
| | | | ATCCTGGAGGCTCATACC |
| Reo3 | M3 | AF174384.1 | AGGCTACAGATGGAGTTGAGT |
| | | | ATGCAAGTGTGGTGTCTCAG |